Oculis raises CHF 15.5 million in an extension of its Series B Financing

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has successfully raised a further CHF 15.5 million in an extension of its Series B financing round bringing the total raised to CHF 35.5 million. The extension round was led by funds managed by Tekla Capital Management LLC and included Nan Fung Life Sciences, both new investors, as well as Oculis’ current investors.

The VISCHER-team advising Oculis is led by Matthias Staehelin (Partner) with Vincent Reardon (Senior Associate) and Vera Portmann (all Corporate).

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.